Clinical trial
PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid…
NCT00028587 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00028587 |
|---|---|
| Title | PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase I and Pharmacologic Study of the Proteasome Inhibitor PS-341 in Combination With Paclitaxel and Carboplatin in Patients With Advanced Malignancies |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | bortezomib, paclitaxel, carboplatin, laboratory biomarker analysis |
| Enrollment | 96 |
| Start date | Dec 1, 2001 |
| Primary completion | Apr 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: